WIXLIB

INVITAE:Bringing genetic information intomainstream medical practiceO VERVI EW FO R I NVESTO RSAPRI L 2016 2016 Invitae Corporation. All Rights Reserved.1

Safe Harbor StatementThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of1995, including statements relating to the company’s expectations regarding its plans for 2016, including revenue levels, thecost of goods sold, the number of billable tests delivered, the number of genes in its test menu, and the nature and extent offuture reimbursement coverage; the company’s expectations regarding continued growth in 2016; and the timing of any newtesting service releases and the benefits and attributes of any such services. Forward-looking statements are subject to risksand uncertainties that could cause actual results to differ materially, and reported results should not be considered as anindication of future performance. These risks and uncertainties include, but are not limited to: the company’s history of losses;the company’s need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; thecompany’s ability to develop and commercialize new tests and expand into new markets; the risk that the company may notobtain or maintain sufficient levels of reimbursement for its tests; risks associated with the company’s ability to use rapidlychanging genetic data to interpret test results accurately and consistently; the company’s ability to compete; laws andregulations applicable to the company’s business, including potential regulation by the Food and Drug Administration; and theother risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in thecompany’s Annual Report on Form 10-K for the year ended December 31, 2015. These forward-looking statements speak onlyas of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.NOTE: Invitae and the Invitae logo are trademarks of Invitae Corporation. All other trademarks and service marks are theproperty of their respective owners. 2016 Invitae Corporation. All Rights Reserved.2

Genetic information has theglobal opportunity to affectbillions of people 2016 Invitae Corporation. All Rights Reserved.3

Invitae’s story:Bringing a new eraof genome-centric healthcareto billions of peopleEveryone has a uniquegenome that has a significantimpact on their healthThere are over 4,000 medicallyimportant genetic tests today –most of which are over-pricedand under-utilizedHigh quality, low pricedgenetic testing will dramaticallyincrease the total market toeveryone with access tohealthcare 2016 Invitae Corporation. All Rights Reserved.4

Genetic conditions affect everyone“Rare” genetic conditions are actually common in the aggregate 5-10%1 in 20 to 1 in 10 of allcancers are likely tohave a hereditary basis0.4%1 in 250 people has agene mutation that maylead to early onsetcardiovascular disease 0.5-5%0.3% 2%1 in 50 new births result in acomplication involving agenetic condition 2-5%1 in 20 to 1 in 50 healthy peoplehas a gene mutation that putsthem at risk for a medicallyactionable condition1 in 20 to 1 in 200 peoplecarry the Factor V Leidenvariant that may increaserisk for blood clotting 100%Everyone is carrying mutationsthat can cause severe illness ina child if the child’s other parentprovides a mutation in thesame gene1 in 300 will have anepileptic seizure duringtheir lifetime 100%Virtually everyone is carryingmutations affecting drug responseEveryone carries mutations in their genome that cause disease, affect drug responseor recessive genetic conditions that may affect their families 2016 Invitae Corporation. All Rights Reserved.5

Historically, genetic testing was limited by costNumber of Genes InvolvedUnknownDiagnostic ge gene panelsHigh riskbreast cancerSmall gene panelsBRCA1Single GeneTestingLimitedVarianttestingSickle-cell anemiaLowHighComplexity of Diagnosis 2016 Invitae Corporation. All Rights Reserved.6

Invitae is changing the cost structure of the industryInvitae offers oneprice per indicationregardless of thenumber of genesExomes/GenomesLarge gene panelsSmall gene panelsCost of increasing genesSingle GeneTestingVarianttestingCostTechnology is improvingquality and creatingeconomy of scaleCost of the first geneIncreasing number of genes 2016 Invitae Corporation. All Rights Reserved.7

Genetic testing is a multi-billion dollar industry today but it’s highly fragmented, inefficient,and prohibitively expensiveInvitae provides a new world of highquality, low cost genetic testingHigh CostVariableQuality§ 55,208 different genetic assays currently availableacross 4,489 disorders and 5,328 genes(GeneTests.org, January 7, 2016)§ Over 673 laboratories and 1,068 clinics(GeneTests.org, January 7, 2016)§ Comprehensive content across all disease areas§ High quality peer-reviewed science§ One-stop online ordering for any and every highquality genetic test§ Quality and content is variable§ Fast turn around times§ Prices can reach into the thousands of dollars andeven tens of thousands for complex tests§ Open and transparent pricing below 1,000for patients and contracted payers withfull reimbursement support§ Turn around times can often be months or more 2016 Invitae Corporation. All Rights Reserved.8

Invitae is well positioned for growth in 2016 and 2017Our MissionOur GoalBring comprehensive geneticinformation into mainstreammedical practice to improvethe quality of healthcare forbillions of peopleAggregate all the world’sgenetic tests into a singleplatform to make geneticsaffordable and accessiblefor everyone201520162017Adult symptomaticPediatric geneticsHealth & wellness 2016 Invitae Corporation. All Rights Reserved.9

Only genetic testing laboratory to aggregate the world’sgenetic tests into a high quality, affordable offering§ Recently expanded beyond cancer and cardiology with metabolicdisorders/newborn screening, neurology, and pediatric/rare diseases§ Now has more than 1,000 genes in production for less than 1,000 –achieved milestone a year early through R&D acceleration 2016 Invitae Corporation. All Rights Reserved.10

Invitae has demonstrated the quality of our service 1,000 patient study head-to-head with MyriadThe Journal of Molecular Diagnostics, Vol. -, No. -, - 3545556575859606162jmd.amjpathol.orgA Systematic Comparison of Traditional andMultigene Panel Testing for Hereditary Breast andOvarian Cancer Genes in More Than 1000 PatientsQ35Q2Stephen E. Lincoln,* Yuya Kobayashi,* Michael J. Anderson,* Shan Yang,* Andrea J. Desmond,y Meredith A. Mills,zGeoffrey B. Nilsen,* Kevin B. Jacobs,* Federico A. Monzon,* Allison W. Kurian,z James M. Ford,z and Leif W. EllisenyxyFrom the Invitae,* San Francisco, California; the Massachusetts General Hospital Cancer Center, Boston, Massachusetts; the Stanford University School ofMedicine,z Stanford, California; and the Harvard Medical School,x Boston, MassachusettsAccepted for publicationApril 28, 2015.Q5Q6Address correspondence toStephen E. Lincoln, Invitae,458 Brannan St, San Francisco,CA 94107. E-mail: steve.lincoln@invitae.com.Gene panels for hereditary breast and ovarian cancer risk assessment are gaining acceptance, eventhough the clinical utility of these panels is not yet fully defined. Technical questions remain,however, about the performance and clinical interpretation of gene panels in comparison withtraditional tests. We tested 1105 individuals using a 29-gene next-generation sequencing panel andobserved 100% analytical concordance with traditional and reference data on 750 comparablevariants. These 750 variants included technically challenging classes of sequence and copy numbervariation that together represent a significant fraction (13.4%) of the pathogenic variantsobserved. For BRCA1 and BRCA2, we also compared variant interpretations in traditional reports tothose produced using only non-proprietary resources and following criteria based on recent (2015)guidelines. We observed 99.8% net report concordance, albeit with a slightly higher variant ofuncertain significance rate. In 4.5% of BRCA-negative cases, we uncovered pathogenic variants inother genes, which appear clinically relevant. Previously unseen variants requiring interpretationaccumulated rapidly, even after 1000 individuals had been tested. We conclude that nextgeneration sequencing panel testing can provide results highly comparable to traditional testingand can uncover potentially actionable findings that may be otherwise missed. Challenges remainfor the broad adoption of panel tests, some of which will be addressed by the accumulation of largepublic databases of annotated clinical variants. (J Mol Diagn 2015, -: 1e12; tigene panel testing has proved useful as a diagnostic toolfor disorders where similar phenotypes can be influenced bymultiple genes.1 Recent advances in next-generation DNAsequencing technology (NGS) have enabled these clinical testsand made them increasingly inexpensive to perform.2,3 Forhereditary cancer syndromes, studies have shown that NGSbased panel tests can uncover potentially actionable findingsthat may be missed by traditional testing paradigms.4e12 Validation studies of clinical NGS assays for hereditary cancergenes have correspondingly been published,4,7,11,13,14 andcertain guidelines exist for their clinical implementation.15e18Patient management experience using these hereditary cancerpanels is growing,4,19,20 although the clinical utility of theseSupported by The Friends Fighting Breast Cancer, the Tracey Davis Q3Memorial Fund, and the Breast Cancer Research Foundation.Q4Disclosures: The funding organizations had no role in the design,conduct, or reporting of this study. Invitae provided the 29-gene panel testresults used in this study. This study was an academic collaboration and nota sponsored research project: no other funding or compensation was provided by Invitae. S.E.L., Y.K., M.J.A., S.Y., G.B.N., and F.A.M. are employees of Invitae and own stock and/or stock options. J.M.F. is a paidmember of Invitae’s advisory board. Separately from this study, J.M.F. andA.W.K. receive research funding from Myriad Genetics. L.W.E. is aconsultant to Bioreference/GeneDx Laboratories. S.E.L. owns stock inIllumina, whose instruments were used in this study.This paper conforms to the STARD guidelines (http://www.stardstatement.org) for reporting of diagnostic cohort studies.Current address of K.B.J., 23andMe, Inc., Mountain View, CA.Copyright ª 2015 American Society for Investigative Pathologyand the Association for Molecular Pathology.Published by Elsevier Inc. All rights 4.009FLA 5.2.0 DTD ! JMDI426 proof ! 22 July 2015 ! 1:34 am ! EO: JMD14 124Analytical validity for BRCA testingAnalytical Concordance – 100%Clinical validity for BRCA testingClinical Concordance – 99.8% 1,000 patient study demonstrating clinical utilityDemonstrated clinical utility beyondBRCA for hereditary cancer panelsbased on NCCN guidelines 2016 Invitae Corporation. All Rights Reserved.11

Invitae offers high quality at lower prices§ One price per indication regardless the number of genes§ Re-requisition at no additional charge within 90 days in original indication§ Patient pay alternative for those who do not meet insurance criteriaList Price 1,500Contracted Price 950*Cost of out-of-networkdenials and appealsPatient payDepends onadministrative criteria 475Upfront payment*Contracted price is as low as 950 per indication depending on administrative criteria 2016 Invitae Corporation. All Rights Reserved.12